Tempus AI
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Tempus AI
Jul 29, 2024, 09:27 |
Career
Ezequiel Renzulli: I am excited to announce the launch of Rio Sur Advisory Partners
Ezequiel Renzulli, Chief Executive Officer at Rio Sur Advisory Partners, shared on LinkedIn: "After six…
Jul 21, 2024, 12:32 |
Blog
CancerX Moonshot's updated Solutions Catalog
CancerX Moonshot shared a post on LinkedIn: "We’ve updated our Solutions Catalog! . The…
Jun 8, 2024, 11:24 |
Blog
Kristiyana Kaneva: Packed several days at ASCO with Tempus AI
Kristiyana Kaneva, Executive Medical Director, Clinical Development at Tempus AI, shared a post on LinkedIn:…
May 1, 2024, 06:04 |
Insight
Martin Stumpe: Predicting MSI in prostate cancer from hematoxylin and eosin stained biopsy
Martin Stumpe, Chief of AI at Tempus, shared on LinkedIn: “We recently published a paper…
Dec 13, 2023, 17:53 |
Blog
Earle Burgess: Why don’t all advanced prostate cancer patients with pathogenic HRR gene mutations respond to parp inhibitors?
Earle Burgess, Chief of Genitourinary Oncology Section at Atrium Health, Levine Cancer Institute, shared a…
All:
5
Posts:
1 - 100
OncoDaily Announces Strategic Partnership with the Asian Fund for Cancer Research Limited (AFCR)
Peyo the Therapy Horse: Comforting Terminally Ill Patients Through Horse Therapy.
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 3
Small Bowel Cancer: Symptoms & Causes, Types, Diagnosis and Treatment
Mikkael A. Sekeres, Candidate for Secretary of ASH
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube